[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-638552-105":59,"doc-detail-638552-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cljn452x2202-patient-summary-clinical-trial-results","CLJN452X2202 Patient Summary - Clinical Trial Results","","Clinical trial results summary for LJN452 (tropifexor), sponsored by Novartis and prepared by CISCRP, describing how the investigational drug was studied in adults with primary bile acid diarrhea (PBAD). The trial compared LJN452 with a placebo in a double-blind design, capturing bowel movement frequency, stool form, drug exposure in blood, rescue medicine use, and safety issues. Participation, study duration, and why the trial ended early are also explained.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cljn452x2202-patient-summary-clinical-trial-results/638552/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cljn452x2202-patient-summary-clinical-trial-results/638552.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-10-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is LJN452 (tropifexor) and what condition was it studied for?","Question",{"text":112,"@type":113},"LJN452, also called tropifexor, was studied in people with primary bile acid diarrhea (PBAD). Researchers aimed to reduce the amount of bile acid produced by the liver to lessen diarrhea.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the trial designed and how were participants assigned treatments?",{"text":117,"@type":113},"The trial was double-blind, so neither participants nor testing staff knew which treatment was given. A computer program randomly assigned participants to LJN452 or a placebo, and each participant took both treatments across two parts.",{"name":119,"@type":110,"acceptedAnswer":120},"Why did the trial end early and what were the enrollment results?",{"text":121,"@type":113},"After reviewing initial results, researchers found LJN452 did not lower PBAD symptoms as much as expected, and it was challenging to find enough suitable participants. The trial included 20 participants across 4 sites in the United Kingdom and the United States.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},638552,1792686285,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":129,"read_time":41,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Clinical Trial Results    \nResearch Sponsor: Novartis  \nDrug Studied: LJN452 (tropifexor)  \nProtocol Number: CLJN452X2202  \nThankyou!  \nThank you for taking part in the clinical trial for the study drug LJN452, also called tropifexor. You and all of the participants helped researchers learn more about how LJN452 works in people with primary bile acid diarrhea, also called PBAD.  \nNovartis sponsored this trial and believes it is important to share the results of the trial with you and the public. An independent non-profit organization called CISCRP prepared this summary of the trial results for you. We hope it helps you understand your important role in medical research.  \nIf you participated in the trial and have questions about the results, please speak with the doctor or staff at your trial site.  \nWhat has happened since the trial ended?  \nYou were in this trial for up to about 3 months. The entire trial lasted about 1 year and 9 months. This is because participants started and stopped at different times. The trial started in April 2016 and ended in January 2018.  \nThe researchers planned to include 30 participants in the trial. But, after reviewing the initial results, they found that LJN452 did not lower PBAD symptoms as much asthe researchers expected. It was also challenging for the researchers to find enough participants with PBAD suitable to join the trial. So, the researchers decided to stop the trial early.  \nThe trial included 20 participants from 4 trial sites in the United Kingdom and the United States. After the trial ended, the sponsor reviewed the data and created areport of the results. This is a summary of that report.  \nWhy was the research needed?  \nResearchers are looking for a better way to treat participants with PBAD. Before a drug can be approved for participants to take, researchers perform clinical trials to find out how safe it is and how well it works. The information collected from many clinical trials is needed to find out if LJN452 improves the health of participants with PBAD.  \nThe liver makes a substance called bile acid that helps people digest their food. Usually, the bile acid is taken up in the small intestine during digestion. But in people with PBAD, not all the bile acid gets taken up by the small intestine. So, the bile acid ends up in the large intestine. This causes diarrhea.  \nLJN452 helps reduce the amount of bile acid that is produced by the liver. Researchers think that by reducing the amount of bile produced by the liver, less bile should reach the large intestine. The researchers think this may help lessen diarrhea in participants with PBAD.  \nIn this trial, the researchers wanted to find out if LJN452 works in a small number of participants with PBAD. They also wanted to find out about the safety of LJN452 in participants with PBAD. To do this, the researchers compared LJN452 with a placebo. A placebo looks like the trial drug but does not have any medicine in it. Using a placebo helps researchers to understand the actual effect of a trial drug better.  \nThe main questions the researchers wanted to answer in this trial were:  \n• Did LJN452 change how often the participants had bowel movements?  \n• Did LJN452 change the form of the participants’ stools?  \n• How much LJN452 got into the participants’ blood?  \n• Did LJN452 change how much rescue medicine the participants used?  \n• What medical problems did the participants have?  \nWhat kind of trial was this?  \nTo answer the questions in this trial, the researchers asked for the help of men and women with PBAD. The participants in this trial were 30 to 75 years old.  \nThis was a “double-blind” trial. This means none of the participants or trial staff performing the tests knew what treatment each participants took. Some trials are done this way because knowing what treatment the participants are taking can affect the results of the trial. Doing a trial this way helps make sure the results are looked at fairly.  \nA computer progr","cbCaieOGbWxASqv3","https://ap.wps.com/l/cbCaieOGbWxASqv3","pdf",337017,12,"English","# About this trial\n## Drug and research sponsor\n## What has happened since the trial ended?\n## Why the research was needed?\n# Trial design\n## What kind of trial was this?\n## Who participated?\n## What happened during the trial?\n# Trial objectives and measures\n## Main questions the researchers wanted to answer","[{\"question\":\"What is LJN452 (tropifexor) and what condition was it studied for?\",\"answer\":\"LJN452, also called tropifexor, was studied in people with primary bile acid diarrhea (PBAD). Researchers aimed to reduce the amount of bile acid produced by the liver to lessen diarrhea.\"},{\"question\":\"How was the trial designed and how were participants assigned treatments?\",\"answer\":\"The trial was double-blind, so neither participants nor testing staff knew which treatment was given. A computer program randomly assigned participants to LJN452 or a placebo, and each participant took both treatments across two parts.\"},{\"question\":\"Why did the trial end early and what were the enrollment results?\",\"answer\":\"After reviewing initial results, researchers found LJN452 did not lower PBAD symptoms as much as expected, and it was challenging to find enough suitable participants. The trial included 20 participants across 4 sites in the United Kingdom and the United States.\"}]","CLJN452X2202 Patient Summary - Clinical Trial Results | PDF"]